Skip to main content
Equibles
LGND logo

LGND · Ligand Pharmaceuticals Inc

Track LGND — free

Use LGND with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$285.60 -4.14 (-1.43%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$5.70B
Shares
19.94M

LGND metrics

81 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$285.60
Market cap
$5.70B

Price action

19 metrics
Price change (1W)
+1.8%
Price change (30D)
-3.5%
Price change (3M)
+22.8%
Price change (6M)
+40.5%
Price change (YTD)
+53.2%
Price change (1Y)
+74.0%
Trailing year
Price change (5Y)
—
52-week high
$322.61
52-week low
$165.41
Change from 52-week high
-10.2%
Change from 52-week low
+75.2%
Annualized volatility
36.0%
Beta
0.8
RSI (14D)
51.1
Price vs SMA 50
-2.7%
Price vs SMA 200
+24.9%
Avg volume (3M)
354,856
Relative volume
0.5
Average dollar volume
$103.29M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.94M

Valuation

12 metrics
P / E (TTM)
30.0
Trailing earnings · reciprocal yield 3.3%
PEG ratio
0.0
EV / revenue
18.8×
reciprocal yield 5.3%
EV / EBITDA
42.8×
reciprocal yield 2.3%
EV / EBIT
57.7×
reciprocal yield 1.7%
P / sales
19.6×
reciprocal yield 5.1%
P / book
5.9
reciprocal yield 17.0%
FCF yield
2.3%
TTM · current market cap
Buyback yield
—
P / FCF
43.4
reciprocal yield 2.3%
P / operating cash flow
43.3
reciprocal yield 2.3%
Earnings yield
3.5%

Historical valuation

8 metrics
P / E historical average (3Y)
43.7×
reciprocal yield 2.3%
P / E historical average (5Y)
45.9×
reciprocal yield 2.2%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
32.6%
Trailing 12 months
Net margin
67.9%
Gross profit (TTM)
—
Operating profit (TTM)
$94.73M
Net income (TTM)
$197.22M
Trailing 12 months
Diluted EPS (TTM)
$9.65
FCF margin
45.2%
Effective tax rate
17.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+33.7%
Year over year
Net income growth YoY
+900.8%
Revenue (TTM)
$290.54M
Trailing 12 months
EPS growth YoY
+825.0%
Shares change YoY
+9.6%
Year over year · more shares
Revenue CAGR (3Y)
+11.0%
Revenue CAGR (5Y)
+10.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-25.8%
FCF CAGR (5Y)
-0.5%

Quality

14 metrics
Return on equity
20.4%
Return on assets
9.0%
Debt / equity
1.2
Current ratio
31.2
EBITDA (TTM)
$127.65M
Free cash flow (TTM)
$131.44M
Quick ratio
31.0
Interest coverage
15.3
Net debt / EBITDA
-1.8
Return on invested capital
10.7%
Trailing 12 months
Net cash
$231.16M
Latest balance sheet
Cash & equivalents
$1.01B
Total assets
$2.19B
Total debt
$1.13B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$131.71M
Capital expenditures (TTM)
$278,000
R&D (TTM)
$41.35M
SG&A (TTM)
—
Stock compensation (TTM)
$53.27M
R&D / revenue
14.2%
Stock compensation / revenue
18.3%

Ownership (13F)

3 metrics
13F filers
420
13F filer change QoQ
+59
Institutional ownership
113.9%

Short interest

3 metrics
Short interest
12.3%
Latest settlement · 8.8 days to cover
Days to cover
8.8d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$18.94M
Insider-sentiment score
14 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 886163 CUSIP 53220K504 13F (30d) 274 filings 266 filers Visit website Investor relations